Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match

Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match
To be or not to be in Medicare? That's the question facing NZX-listed Pacific Edge. (Image: Pacific Edge)
Rebecca Stevenson
The head of listed cancer diagnostics company Pacific Edge says its singular focus on the United States market is not a single point of failure. Pacific Edge’s share price has taken a hammering after it announced earlier this year it could lose access to the US Medicare system after Novitas – which administers Medicare – determined the Dunedin-based company’s products did not meet new thresholds for coverage under the US Social Security Act. On Monday, its shares were again buffeted by negative news when the US...

More Markets

NZ sharemarket claws back to end the week up 0.5%
Markets Market close

NZ sharemarket claws back to end the week up 0.5%

Index rumours drive prices on two shares. 

Graham Skellern 13 Dec 2024
Staff leave Meridian after retail 'reset'
Markets

Staff leave Meridian after retail 'reset'

Expect a very different approach from Meridian in 2025, executive says.

John Anthony 13 Dec 2024
NZX, NZSA want level playing field in climate reporting
Markets

NZX, NZSA want level playing field in climate reporting

Climate reporting liabilities for company directors could soon be eased.

Greg Hurrell 13 Dec 2024
Cannasouth delisting keeps Petterson in charge
Markets

Cannasouth delisting keeps Petterson in charge

Cannasouth major shareholders pushed to end voluntary administration they had called in.

Garth Bray 13 Dec 2024